News Release

Printer Friendly VersionView printer-friendly version << Back



AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering

REDWOOD CITY, Calif., Nov. 12, 2010 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by the Company.

Piper Jaffray & Co. is acting as sole book-running manager. Canaccord Genuity Inc., Cowen and Company, LLC and JMP Securities are acting as co-managers for the offering. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from Piper Jaffray & Co., 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, Telephone 1-800-747-3924.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About AcelRx Pharmaceuticals

AcelRx AcelRx Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.

Contact:
Jim Welch,
Chief Financial Officer of AcelRx Pharmaceuticals, Inc.,
+1-650-216-3511,
jwelch@acelrx.com